Custom Search

Wednesday, September 17, 2014

Carl Domino-Action Hero



Don't let that video out! BO

Thursday, March 6, 2014

Whitney Tilson gets behind SODA

Noted shortseller Tilson now says Sodastream, SODA at 41 and change isn't a fad, comparing its potential to a NFLX or GGP since people love the product (a soda for your cocktail to go with your movies and malls).

Recluse makes nuclear reactor


Upskirt photos are legal says Massachusetts high court

(CNN) -- Massachusetts' highest court ruled Wednesday that it is not illegal to secretly photograph underneath a person's clothing -- a practice known as "upskirting" -- prompting one prosecutor to call for a revision of state law.

 The high court ruled that the practice did not violate the law because the women who were photographed while riding Boston public transportation were not nude or partially nude.

 "A female passenger on a MBTA trolley who is wearing a skirt, dress, or the like covering these parts of her body is not a person who is 'partially nude,' no matter what is or is not underneath the skirt by way of underwear or other clothing," wrote Justice Margot Botsford of the state Supreme Judicial Court.


Upskirts are legal which means down markets will be banned next! Or allowing the taxpayer to see if there's any gold!  You can't touch that!

Wednesday, March 5, 2014

Facebook's Drone Purchase


These solar power drones can stay in the air for 5 years. And they will start in Africa. Titan's website is here. And from that:

Titan Aerospace’s SOLARA Platforms Capable of Supporting Wide Range of Voice and Data Communications
Applications:
  • Range extension of line of sight communication systems
  • Range extension of line of sight data transmission systems
  • Supports VHF, UHF, and microwave frequencies


 Facebook will use these to compete with Google's Project Loon!

Yes Loons. As in hot air balloons.



Facebook is trying to out hustle Google, by giving the internet to the world, before Google can blow up their balloons.
(image courtesy of Colonel Flick)

And it's cheaper than laying undersea cables that the NSA can spy on.

And it only cost $60 million to start.

Which is the next step in making What's App worth the $19 billion Facebook will have paid!

Peregrine Pharmaceuticals (PPHM) pops to $2.82

Earnings in two days and then below:

Maybe now it will soar. (That's the Peregrine Falcon, the fastest moving creature on earth--Its here for a reason! It's only the first day up!)

PRESENTATION DETAILS:
CONFERENCE: IMMUNE EVOLUTION IN CANCER Plenary Talk: Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage Polarization, Promote Myeloid Derived Suppressor Cell Differentiation and Boost Tumor-Specific Immunity
Presenter: Xianming Huang, Ph.D., Assistant Professor, Hamon Center for Therapeutic Oncology, Pharmacology, Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center, Dallas, Texas
Date: Wednesday, March 12, 2014
Time: 2:30 P.M. - 4:30 P.M. Pacific Time
Workshop: #3: Immune Suppressive Myeloid Cells
Location: MacDonald DEF Room, Fairmont Chateau Whistler, Whistler, British Columbia, Canada


CONFERENCE: IMMUNE EVOLUTION IN CANCERTitle: Phosphatidylserine Targeting Antibodies Enhance the Activity of Immune Checkpoint Inhibitors in Tumors
Presenter: Bruce Freimark, Ph.D., Director of Pre-Clinical Research Oncology, Peregrine Pharmaceuticals
Poster: Poster Session 1 - Poster 1029
Date: Monday, March 10, 2014
Viewing: 1:00 P.M. - 10:00 P.M. Pacific Time
Presentation: 7:30 P.M. - 10:00 P.M. Pacific Time
Location: Frontenac Ballroom and Foyer - Fairmont Chateau Whistler, Whistler, British Columbia, Canada
CONFERENCE: HIV PATHOGENESIS VIRUS VERSUS HOST Title: Phosphatidylserine-Targeting Antibody Triggers B-Chemokine Release from Monocytes by Cell-Cell Crosslinking and is a Potent Inhibitor of HIV-1 In Vitro
Presenter: Cyril Empig, Ph.D., Associate Director, Pre-Clinical Research Infectious Disease, Peregrine Pharmaceuticals
Poster: Poster Session 3 - Poster 3020
Date: Wednesday, March 12, 2014
Viewing: 1:00 P.M. - 10:00 P.M. Mountain Time
Presentation: 7:30 P.M. - 10:00 P.M. Mountain Time
Location: Mezzanine 2 - Fairmont Banff Springs, Alberta, Canada
About Bavituximab: A Targeted ImmunotherapyBavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor. These data detailing the immune-stimulatory mechanism of action of PS-targeting antibodies, such as the company's lead drug candidate bavituximab, are the subject of a manuscript published in the October 2013 issue of the American Association for Cancer Research (AACR) peer-reviewed journal, Cancer Immunology Research. Bavituximab is currently being evaluated in several solid tumor indications, including non-small cell lung cancer, breast cancer, liver cancer and rectal cancer with a trial in advanced melanoma anticipated to initiate in the near future.

Huvrtech Huvverboards



Huvrtech.com